[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Barbados\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":147},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,79,123],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100297409","international-registry-for-men-with-advanced-prostate-cancer-ironman-100297409",false,"NCT03151629","International Registry for Men With Advanced Prostate Cancer (IRONMAN)","IRONMAN","• Willing and able to provide written informed consent and privacy authorization for the release of personal health information.\n\nNOTE: Privacy authorization may be either included in the informed consent or obtained separately.\n\n* Males 21 years of age and above\n* Histological or cytological confirmed prostate adenocarcinoma from TRUS biopsy, radical prostatectomy or TURP Or Documented histopathology or cytopathology of prostate adenocarcinoma from a biopsy of a metastatic site Or Metastatic disease typical of prostate cancer (i.e., involving bone or pelvic lymph nodes or para-aortic lymph nodes) AND a serum concentration of PSA \\>20ng\u002FmL at the time of initial prostate cancer diagnosis\n* No previous diagnosis of a second, non-prostate malignancy that requires additional systemic therapy except cancer in situ of bladder and basal cell cancer of skin","MALE","21 Years",{"count":19,"type":20},5000,"ESTIMATED","5 Years","OBSERVATIONAL","Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0\u002FM1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingdom (UK), and the United States (US). Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices.\n\nDetailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of five years. Patients will be followed prospectively for overall survival, clinically significant adverse events, comorbidities, changes in cancer treatments, and PROMs.\n\nPROMs questionnaires will be collected at enrollment and every three months thereafter.\n\nPhysician Questionnaires will be collected from all participating sites at patient enrollment, time of first change in treatment and\u002For one year follow-up, at each subsequent change of treatment, and discontinuation of treatment.\n\nAs such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs for men with mHSPC and M0\u002FM1 CRPC. By collecting blood at enrollment, time of first change in treatment and\u002For one year follow-up (plasma, cell free DNA, buffy coat \u002F RNA), this registry will further identify and validate molecular phenotypes of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen at each subsequent change in treatment due to progression of disease. When feasible, existing tumor tissue may be collected for correlation with described blood based studies. All samples will be used for future research. This cohort study will provide the research community with a unique biorepository to identify biomarkers of treatment response and resistance.",[25],"Prostate Cancer","RECRUITING","2026-05-19",{"date":29,"type":30},"2026-05-22","ACTUAL",{"date":32,"type":30},"2017-07-21",{"date":34,"type":20},"2032-01",{"name":36,"class":37},"Prostate Cancer Clinical Trials Consortium","OTHER",121,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":46,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100633598","phase-2-gemcitabine-vs-paclitaxel-in-caribbean-women-of-african-ancestry-with-metastatic-triple-negative-breast-cancer-100633598","NCT07528768","Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer","Breaking Barriers in Breast Cancer Treatment for the Caribbean - Gemcitabine Versus Standard First-Line Chemotherapy in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer","Inclusion Criteria:\n\n1. Self-identified Caribbean Black women of Jamaican, Trinidadian, or Barbadian ancestry\n2. Age ≥18 years\n3. Histologically confirmed metastatic triple-negative breast cancer (recent biopsy required)\n4. ECOG (Eastern Cooperative Oncology Group) performance status 0-1\n5. No prior systemic therapy for metastatic disease\n6. Adequate organ function (detailed laboratory criteria specified)\n7. Written informed consent\n8. Willingness to provide biospecimens for research\n\nExclusion Criteria:\n\n1. Prior gemcitabine, anthracycline, or taxane treatment in any setting\n2. Active brain metastases requiring immediate treatment\n3. Pregnant or breastfeeding\n4. Concurrent participation in other interventional trials\n5. Medical conditions precluding safe chemotherapy administration\n6. Inability to provide informed consent","FEMALE","18 Years",{"count":49,"type":20},750,"INTERVENTIONAL",[52],"PHASE2","The goal of this clinical trial is to learn if Gemcitabine, a chemotherapy drug that is usually used to treat breast cancer after other treatments have failed, is better at treating triple negative breast cancer in Black Caribbean women than Paclitaxel, one of the chemotherapy drugs that is usually used first. People will be invited to participate in the trial if they are Caribbean women of African ancestry, are 18 years or older, have had a biopsy that shows that they have triple negative breast cancer (TNBC), and are willing to take part.\n\nThe main questions the trial aims to answer are:\n\n1. Does Gemcitabine stop triple negative breast cancer from growing or spreading better than Paclitaxel?\n2. Are participants more likely to get better when taking Gemcitabine or Paclitaxel?\n3. What medical problems do participants have when taking Gemcitabine for breast cancer?\n4. Do Gemcitabine and Paclitaxel affect Black Caribbean women differently than women from other regions or ethnic groups?\n\nTo answer these questions, half of participants will be treated with Gemcitabine while half is treated with Paclitaxel. Both drugs are given by injection and have already been approved for breast cancer treatment. Participants will:\n\n* Take Gemcitabine for two weeks followed by a two-week break, or take Paclitaxel once a week for the same time period.\n* Have some of the cancer tissue that was tested from their biopsy taken for more testing.\n* Have a physical exam and a blood test done every 3 weeks.\n* Have images of their cancer taken using CT (Computed Tomography) or MRI (Magnetic Resonance Imaging) every 6 weeks.\n* Answer a brief questionnaire about how they are feeling every 8 weeks.\n* Be checked on every month after treatment is finished to make sure the cancer hasn't come back.",[55,56],"Triple Negative Breast Cancer","Metastatic Triple-negative Breast Cancer",[58,59,60,61,62,63,64,65,66,67],"Triple Negative Breast Neoplasms","Gemcitabine","Paclitaxel","Progression-Free Survival","Overall Survival","Quality of Life","Caribbean","Jamaica","Trinidad and Tobago","Barbados","NOT_YET_RECRUITING","2026-04-10",{"date":71,"type":30},"2026-04-14",{"date":73,"type":20},"2026-06-01",{"date":75,"type":20},"2034-06-01",{"name":77,"class":37},"AntiCancer Research Jamaica",3,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":46,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":50,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100604471","teen-mothers-reproductive-and-behavioral-health-intervention-in-barbados-100604471","NCT07149948","Teen motHers' ReproductIve and behaVioral Health intErvention in Barbados","Teen motHers' ReproductIve and behaVioral Health intErvention in Barbados (THRIVE)","THRIVE","Inclusion Criteria:\n\n* Young mothers aged 10 to 25 years residing in Barbados\n* Experienced adolescent pregnancy between ages 10 and 19 years\n* Living in low-income households with annual income BDS $20,000 (\\~USD 10,000) or below\n* Screen positive for depressed mood symptoms using the Patient Health Questionnaire-2 (PHQ-2), indicating feeling \"little interest or pleasure in doing things\" and\u002For feeling \"down, depressed, or hopeless\" over the past 2 weeks\n* Able to provide informed consent or assent (with parental consent if under legal age)\n* Willing to complete study questionnaires and attend scheduled visits\n\nExclusion Criteria:\n\n* History of heart disease, head trauma, hypertension, diabetes, psychiatric, or neurological conditions\n* Severe cognitive or medical conditions preventing participation\n* Enrollment in conflicting interventional studies\n* Insufficient proficiency in study languages without access to interpretation (if applicable)","10 Years","25 Years",{"count":90,"type":20},50,[92],"NA","The goal of this clinical trial is to learn if an integrated care program can help improve overall health and prevent repeat pregnancy in teen mothers in Barbados. The study focuses on young women ages 10 to 25 who became pregnant during their teenage years and are experiencing stress or mood-related symptoms. This study is currently pending ethics committee review and has not yet begun enrolling participants.\n\nThe main questions it aims to answer are:\n\n* Does the THRIVE program improve participants' mental health and parenting skills?\n* Does the program help prevent repeat, unplanned pregnancies?\n\nResearchers will compare participants who receive the THRIVE program to those who receive standard care to see if the program leads to better physical and emotional health.\n\nParticipants will:\n\n* Take part in seven biweekly in-person or virtual sessions focused on reproductive and behavioral health;\n* Complete health checks and questionnaires about their mood, parenting stress, and support;\n* Receive follow-up contact after the sessions are completed.\n\nThe THRIVE program includes education on sexual health, mental health, parenting, and life skills. Participants will receive small incentives and support throughout the study. All study activities will begin only after full ethics approval is obtained.",[95],"Pregnancy in Adolescence",[97,67,98,99,100,101,85,102,103,104,105,106,107,108,109,110,111,112,113],"Integrated care","Caribbean health","Psychoeducation","Community-based intervention","Global Health","Adolescent Pregnancy","Teenage Mothers","Parenting","Reproductive Health","Mental Health","School Reentry","Family Planning Services","Contraceptive Use","Low-Income Population","Behavioral Health","Anxiety","Depression","2026-01-01",{"date":116,"type":30},"2026-01-06",{"date":73,"type":20},{"date":119,"type":20},"2028-12-30",{"name":121,"class":37},"Hada Fongha Ieong, PhD",1,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":130,"minAge":4,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":50,"phases":133,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":122},"100564768","early-phase-1-clinical-study-aimed-at-evaluating-the-safety-and-efficacy-of-tear-substitute-formulations-in-the-treatment-of-dry-eye-disease-100564768","NCT06633471","Clinical Study Aimed At Evaluating the Safety and Efficacy of Tear Substitute Formulations in the Treatment of Dry Eye Disease.","A Single-Center, Double- Masked, Randomized Study Evaluating the Safety and Efficacy of PS Therapy (PST) Tear Substitute Formulations in the Treatment of the Signs and Symptoms of Moderate Dry Eye Disease.","Inclusion Criteria:\n\nEach subject must:\n\n1. Be at least 18 years of age at the Screening Visit;\n2. Of either gender and any race;\n3. Be willing and able to follow all instructions and attend all study visits;\n4. Have ALL of the following in the study eye1 at the Screening Visit:\n\n   1. A corneal fluorescein staining score of ≥ 2 in at least one corneal region OR have a sum of ≥ 4 in all corneal regions\n   2. A baseline Schirmer's Test (with topical anesthesia) Score of ≥ 2 millimeters (mm)\u002F and ≤ 10 mm\u002F5 minutes\n   3. A physician's diagnosis of Dry Eye Disease\n5. Have normal lid\u002Flash anatomy, blinking function and closure as determined by the Investigator;\n6. Be literate and able to complete questionnaires independently;\n7. Have sufficient hand strength, in the opinion of the Investigator, to be able to independently administer the study drug;\n8. For females capable of becoming pregnant, agree to have urine pregnancy testing performed at screening (must be negative) and exit visits; must not be lactating; and must agree to use a medically acceptable form of birth control throughout the study. Women considered capable of becoming pregnant include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months), or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy).\n\nExclusion Criteria:\n\nEach subject must not:\n\n1. Have a known hypersensitivity to any of the procedural agents or study drug components, or have previously used the study drug;\n2. Have clinically significant corneal epithelial defects at Visit 1, prior to performing Schirmer's Test;\n3. Have had any intraocular surgery (such as cataract surgery) or extraocular surgery in either eye within three months, or refractive surgery (e.g., laser-assisted in-situ keratomileusis, laser epithelial keratomileusis, photorefractive keratectomy or corneal implant) within twelve months of Visit 1;\n4. Have had blepharoplasty in either eye;\n5. Have had a corneal transplant in either eye;\n6. Have used Restasis® or Xiidra® in the past 60 days;\n7. Be using any ocular medications, other than the study treatment, within 7 days prior to Visit 1 and throughout the study treatment period. This includes both therapeutic and lubricant eye drops that could potentially interfere with the study outcomes, by either exacerbating or alleviating the symptoms of dry eye disease.\n8. Have used contact lenses within 7 days prior to Visit 1 or anticipate the use of contact lenses during the study treatment period;\n9. Have any form of punctal or intracanalicular occlusion;\n10. Have a history or presence of any ocular disorder or condition in either eye that would, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety such as significant corneal or conjunctival scarring; pterygium or nodular pinguecula; current ocular infection, conjunctivitis, or inflammation not associated with dry eye; anterior (epithelial) basement membrane corneal dystrophy or other clinically significant corneal dystrophy or degeneration; ocular herpetic infection; evidence of keratoconus; etc. Blepharitis not requiring treatment and mild meibomian gland disease that are typically associated with DED are allowed;\n11. Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study, or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.);\n12. Have active or uncontrolled, severe:\n\n    * Systemic allergy\n    * Chronic seasonal allergies at risk of being active during the study\n13. Have any condition or history that, in the opinion of the Investigator, may interfere with study compliance, outcome measures, safety parameters, and\u002For the general medical condition of the subject;\n14. Be currently enrolled in an investigational drug or device study, or have used an investigational drug or device within 30 days prior to Visit 1 and during the treatment period;\n15. Be a female who is currently pregnant, planning a pregnancy or lactating.","ALL",{"count":132,"type":20},175,[134],"EARLY_PHASE1","This clinical study is aimed at evaluating the safety and effectiveness of 2 test formulations (Rain and Mist), against an approved over-the-counter formulation (Systane Ultra) and a placebo (saline), in the treatment of moderate dry eye disease.",[137],"Dry Eye Disease (DED)","2024-10-08",{"date":140,"type":30},"2024-10-09",{"date":142,"type":20},"2024-11-04",{"date":144,"type":20},"2025-04-30",{"name":146,"class":37},"PS Therapy Inc.",""]